a Study Evaluating the Safety and Efficacy of Clevidipine for Patients Who With Hypertensive Emergency and Sub-emergency
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 378 participants.
Also called NCT05922436
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 378 participants
- Sponsor
- Qilu Pharmaceutical (Hainan) Co., Ltd.
- Registry
-
NCT05922436
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT05922436. Randomized; triple masking; primary purpose treatment. Start 2023-07-15 (anticipated); primary completion 2024-05-24 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- a Study Evaluating the Safety and Efficacy of Clevidipine for Patients Who With Hypertensive Emergency and Sub-emergency
- Condition
- Hypertensive Emergency
- Intervention (Drug)
- QLG2071
- Intervention (Drug)
- Cleviprex®
- Lead sponsor
- Qilu Pharmaceutical (Hainan) Co., Ltd.
Record details
- Record id
cardio:ct-nct05922436- Content hash
027ce9b021f54a743329d4341b9140a8e389d85e875543a935b5374203566e42